Human Oncology & Pathogenesis Program
The Emily Cheng Lab
Research
The focus of the Cheng laboratory is to elucidate the molecular mechanisms of cell death with an overarching goal of directly translating cell death mechanisms into novel anti-cancer therapeutic strategies that can effectively trigger cancer cell death and enhance anti-cancer immunity.
Publications Highlights
People
Emily H. Cheng, MD, PhD
Attending Pathologist, Department of Pathology; Member, Human Oncology and Pathogenesis Program
- Physician-scientist Emily Cheng studies the molecular mechanisms of cell death and their implications in tumorigenesis, tumor-microenvironment interactions, targeted therapy, and immunotherapy.
- MD, Taipei Medical University
- PhD, Johns Hopkins University School of Medicine
- [email protected]
- Email Address
- 646-888-3258
- Office Phone
Members
- BS, Tsinghua University
Lab Alumni
Lab Affiliations
Achievements
- Distinguished Investigator Award, Washington University School of Medicine (2010)
- Searle Scholar Award (2005)
- Howard Temin Award, National Cancer Institute (2003)
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Career Opportunities
Get in Touch
-
Lab Head Email
-
Office Phone
-
Office Fax
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Emily H. Cheng discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].